BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin

被引:11
作者
Infante, M. [1 ]
Duran, M. [1 ]
Acedo, A. [1 ]
Perez-Cabornero, L. [1 ]
Sanz, D. J. [1 ]
Garcia-Gonzalez, M. [2 ]
Beristain, E. [3 ]
Esteban-Cardenosa, E. [4 ]
de la Hoya, M. [5 ,6 ]
Teule, A.
Vega, A. [7 ]
Tejada, M-I [3 ]
Lastra, E. [2 ]
Miner, C. [1 ]
Velasco, E. A. [1 ]
机构
[1] UVa CSIC, Grp Genet Canc, Inst Biol & Genet Mol, Valladolid 47003, Spain
[2] Hosp Gen Yague, Serv Oncol, Burgos, Spain
[3] Hosp Cruces, Genet Mol Lab, Dept Bioquim, Baracaldo, Spain
[4] Hosp Univ La Fe, Mol Biol Lab, Serv Biopatol Clin, Valencia, Spain
[5] Hosp Clin San Carlos, Oncol Mol Lab, Madrid, Spain
[6] Inst Salud Carlos III, Spanish Minist Sci & Innovat, Madrid, Spain
[7] CIBERER, FPGMX, SERGAS, Santiago De Compostela, Spain
关键词
BRCA1; BRCA2; breast cancer; founder mutations; ovarian cancer; BREAST-CANCER; HIGH PROPORTION; HETERODUPLEX ANALYSIS; PHENOTYPE ANALYSIS; HAPLOTYPE; POPULATION; IDENTIFICATION; FREQUENCY; RISKS; SPAIN;
D O I
10.1111/j.1399-0004.2009.01272.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The distribution of BRCA1 and BRCA2 germ line mutations in breast/ovarian cancer families varies among different populations, which typically present a wide spectrum of unique mutations. Splicing mutation 5272-1G > A of BRCA1 and frameshift mutation 5374delTATG of BRCA2 are highly prevalent mutations in Castilla-Leon (Spain), accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively. To test the presence of founder effects, 9 Spanish 5272-1G > A and 13 5374delTATG families were genotyped with polymorphic markers linked to BRCA1 or BRCA2. All the 5272-1G > A families shared a common haplotype in eight markers (1.1 Mb region) and the mutation age was estimated in 15 generations (similar to 380 years). A conserved haplotype associated to 5374delTATG was observed in four markers (0.82 Mb). The mutation occurred approximately 48 generations ago (similar to 1200 years). Each mutation likely arose from a common ancestor that could be traced to a small area of Castilla-Leon and expanded to other Spanish regions. They can have a significant impact on the clinical management of asymptomatic carriers as well as on the genetic screening strategy to be followed in populations with Spanish ancestries.
引用
收藏
页码:60 / 69
页数:10
相关论文
共 50 条
  • [41] Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling
    E. Beristain
    C. Martínez-Bouzas
    I. Guerra
    N. Viguera
    J. Moreno
    E. Ibañez
    J. Díez
    F. Rodríguez
    G. Mallabiabarrena
    S. Luján
    J. Gorostiaga
    J. L. De Pablo
    J. L. Mendizabal
    M. I. Tejada
    Breast Cancer Research and Treatment, 2007, 106 : 255 - 262
  • [42] Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients:: A high proportion of mutations unique to Spain and evidence of founder effects
    Díez, O
    Osorio, A
    Durán, M
    Martinez-Ferrandis, JI
    de la Hoya, M
    Salazar, R
    Vega, A
    Campos, B
    Rodríguez-López, R
    Velasco, E
    Chaves, J
    Díaz-Rubio, E
    Cruz, JJ
    Torres, M
    Esteban, E
    Cervantes, A
    Alonso, C
    San Román, JM
    González-Sarmiento, R
    Miner, C
    Carracedo, A
    Armengod, ME
    Caldés, T
    Benítez, J
    Baiget, M
    HUMAN MUTATION, 2003, 22 (04) : 301 - 312
  • [43] High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients
    Fackenthal, James D.
    Zhang, Jing
    Zhang, Bifeng
    Zheng, Yonglan
    Hagos, Fitsum
    Burrill, Devin R.
    Niu, Qun
    Huo, Dezheng
    Sveen, Walmy E.
    Ogundiran, Temidayo
    Adebamowo, Clemet
    Odetunde, Abayomi
    Falusi, Adeyinka G.
    Olopade, Olufunmilayo I.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : 1114 - 1123
  • [44] Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing
    Riahi, Aouatef
    Chabouni-Bouhamed, Habiba
    Kharrat, Maher
    CANCER GENETICS, 2017, 210 : 22 - 27
  • [45] Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families
    Ikeda, N
    Miyoshi, Y
    Yoneda, K
    Shiba, E
    Sekihara, Y
    Kinoshita, M
    Noguchi, S
    INTERNATIONAL JOURNAL OF CANCER, 2001, 91 (01) : 83 - 88
  • [46] The patterns and spectrum of BRCA1 and BRCA2 mutations in Iranian breast and ovarian cancer patients
    Shayan Forghani
    Hamid Reza Mirzaee
    Hamid Rezvani
    Arman Forghani
    Fatemeh Mahdavi Sabet
    Ali Hojjat
    Mona Malekzadeh
    Atieh Akbari
    Sanaz Tabarestani
    Familial Cancer, 24 (2)
  • [47] BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer
    El Saghir, Nagi S.
    Zgheib, Nathalie K.
    Assi, Hussein A.
    Khoury, Katia E.
    Bidet, Yannick
    Jaber, Sara M.
    Charara, Raghid N.
    Farhat, Rania A.
    Kreidieh, Firas Y.
    Decousus, Stephanie
    Romero, Pierre
    Nemer, Georges M.
    Salem, Ziad
    Shamseddine, Ali
    Tfayli, Arafat
    Abbas, Jaber
    Jamali, Faek
    Seoud, Muhieddine
    Armstrong, Deborah K.
    Bignon, Yves-Jean
    Uhrhammer, Nancy
    ONCOLOGIST, 2015, 20 (04) : 357 - 364
  • [48] Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations
    Kim, Daniel H.
    Crawford, Beth
    Ziegler, John
    Beattie, Mary S.
    FAMILIAL CANCER, 2009, 8 (02) : 153 - 158
  • [49] BRCA1 and BRCA2 genetic test in high risk patients and families: Counselling and management
    Marchina, Eleonora
    Fontana, Maria Grazia
    Speziani, Michela
    Salvi, Alessandro
    Ricca, Giuseppe
    Di Lorenzo, Diego
    Gervasi, Maria
    Caimi, Luigi
    Barlati, Sergio
    ONCOLOGY REPORTS, 2010, 24 (06) : 1661 - 1667
  • [50] Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations
    Thomas v. O. Hansen
    Lars Jønson
    Ane Y. Steffensen
    Mette K. Andersen
    Susanne Kjaergaard
    Anne-Marie Gerdes
    Bent Ejlertsen
    Finn C. Nielsen
    Familial Cancer, 2011, 10 : 207 - 212